Overview

A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer

Status:
Recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

-Interventional trials aim at preventing severe RIF occurrence in BC patients selected by individual radiosensitivity: PRAVAPREV-01 will be the first interventional double blind trial that will offer a personalised strategy to breast cancer patients who will be treated with adjuvant RT after breast conserving surgery: - By assessing individual risk of severe RIF development - By offering a statin targeted therapy to the high-risk patients identified.

Phase:

Phase 3

Details

Lead Sponsor:

Institut du Cancer de Montpellier - Val d'Aurelle

Treatments:

Pravastatin